Bristol Myers' Opdivo combo Opdualag scores FDA approval in melanoma, opens 3rd immune checkpoint drug class 3 kidney care providers—Fresenius Health Partners, Cricket Health and InterWell Health—plan to merge in deal valued at $2.4B Bristol Myers lands $1.1B biobucks oncology pact with Volastra, a biotech with phones 'ringing off the hook' Medtech's top 10 money raisers of 2021 As AstraZeneca sounds the slowdown alarm in China, Jefferies beats the drum for growing branded drug market Immunogen's phase 3 ADC survival data spook investors, sending stock down ahead of FDA filing Philips’ ventilator woes drag on with yet another Class I recall Pfizer gets an A on equality scorecard on Equal Pay Day Becerra: HHS wants to get 'money's worth' on Medicare Advantage, will look into coding practices After price deal, Takeda's lung cancer drug Exkivity wins UK green light ahead of J&J rival Chasing Big Pharma trio, Bavarian Nordic sells Chinese rights to RSV vaccine candidate in $225M deal Pear Therapeutics snags SoftBank backing to bring digital therapeutic tech for sleep disorders to Japan DaVita CEO Javier Rodriguez talks integrated kidney care, competitive threats and regulation MIT, Mass General researchers develop handheld robot for tapping into blood vessels Cloaking bacteria via tunable gene circuits for cancer treatment #FierceMadness: And then there were 32: BioMarin's Voxzogo takes the biggest win; get voting for your Sweet 16 Featured Story | By Angus Liu Bristol Myers Squibb has established the third cancer checkpoint inhibitor class, going back to its immuno-oncology roots in melanoma with an FDA go-ahead. read more |
| |
|---|
|
Top Stories By Heather Landi Three big players in the kidney care market—Fresenius Health Partners, Cricket Health and InterWell Health—plan to form a new value-based care company. The deal, announced Monday morning, is valued at more than $2 billion, according to the companies. read more By Max Bayer Two years since its inception, Volastra Therapeutics is partnering with Bristol Myers Squibb for up to three oncology targets focused on chromosomal instability, a deal that could exceed $1.1 billion should the assets hit milestones. read more By Andrea Park,Conor Hale The medtech industry’s impressive venture funding activity was an anomaly in 2020, when most other sectors were floundering to stay afloat during the COVID-19 pandemic. A year later, as businesses around the globe returned to (somewhat) normal operations and overall VC activity hiked back up, medtech continued to ride that wave, coasting to its highest-ever annual funding total by the end of 2021. read more By Angus Liu China's aggressive efforts to lower drug costs are unnerving some investors. But analysts at Jefferies argue the good days of growth are not over yet, projecting that the country's branded drug market could reach $85 billion in 2030. read more By Nick Paul Taylor Immunogen’s full data on mirvetuximab soravtansine have underwhelmed investors. While the biotech is racing to the FDA with the results, its stock fell around 20% to below $5 in premarket trading after the release of survival data that fell short of investor expectations. read more By Andrea Park The company’s V60 and V60 Plus ventilators for high-flow oxygen therapy have now sparked two separate Class I recalls since last summer. read more By Sharon Klahr Coey On Tuesday, March 15, Equal Pay Day, Capital and Proxy Impact released the fifth Racial and Gender Pay Scorecard, and, surprise—women and people of color are still being paid less than their white male counterparts. read more By Robert King HHS Secretary Xavier Becerra said the agency is looking into practices such as up-coding Medicare Advantage plans use to get overpayments from traditional Medicare, adding he doesn't want taxpayers to be "duped." read more By Kevin Dunleavy England has conditionally approved Takeda’s Exkivity for non-small cell lung cancer patients whose tumors have epidermal growth factor receptor (EGFR) exon 20 insertion mutations after chemotherapy and disease progression. In the rare form of the disease, Takeda is battling Johnson & Johnson's Rybrevant. read more By Nick Paul Taylor Bavarian Nordic has found a taker for the Chinese rights to its RSV vaccine candidate. Nuance Pharma has taken the other side of the deal, handing over $12.5 million and committing to $212.5 million more in milestones to license the vaccine in China, South Korea and some other markets in Southeast Asia. read more By Andrea Park Through the agreement, as Pear begins building the Japanese-language software, SoftBank will provide information about the Japanese market to help shape the technology. Once the software is ready for distribution, the Tokyo-based company will have the option to negotiate an exclusive licensing deal in the country. read more By Dave Muoio Fierce Healthcare caught up with the CEO for a 2022 update on his company's shift from dialysis to kidney care, whether recent legal cases limit DaVita’s opportunities for growth and more. read more By Conor Hale The system uses an artificial intelligence-powered ultrasound scanner to guide needles and catheter hardware, to help stem severe bleeding or deliver fluids and medications all while potentially in the back of an ambulance. read more By Angus Liu Inspired by a natural mechanism to protect bacteria, bioengineers at Columbia University have developed a programmable “cloaking” system that could temporarily hide bacterial vehicles from the immune system to better deliver cancer therapies. read more By Ben Adams It’s March, so it’s time for some #FierceMadness. We’re looking for the best of the best in drug names—and now it's time to get voting for your Sweet 16. read more |
